N
Natalya Gubergrits
Researcher at Donetsk National Medical University
Publications - 41
Citations - 1147
Natalya Gubergrits is an academic researcher from Donetsk National Medical University. The author has contributed to research in topics: Medicine & Pancreatitis. The author has an hindex of 8, co-authored 25 publications receiving 756 citations.
Papers
More filters
Journal ArticleDOI
European evidence-based guidelines on pancreatic cystic neoplasms
Marco Del Chiaro,Marc G. Besselink,Lianne Scholten,Marco J. Bruno,Djuna L. Cahen,Thomas M. Gress,Jeanin E. van Hooft,Markus M. Lerch,Julia Mayerle,Thilo Hackert,Sohei Satoi,Alessandro Zerbi,David Cunningham,Claudio De Angelis,Marc Giovanni,Enrique de-Madaria,Péter Hegyi,Jonas Rosendahl,Helmut Friess,Riccardo Manfredi,Philippe Lévy,Francisco X. Real,Alain Sauvanet,Mohammed Abu Hilal,Giovanni Marchegiani,Irene Esposito,Paula Ghaneh,Marc R. W. Engelbrecht,Paul Fockens,Nadine C.M. van Huijgevoort,Christopher L. Wolfgang,Claudio Bassi,Natalya Gubergrits,Caroline S. Verbeke,Günter Klöppel,Aldo Scarpa,Giuseppe Zamboni,Anne Marie Lennon,Malin Sund,Nikolaos Kartalis,Lars Grenacher,Massimo Falconi,Urban Arnelo,Kostantin V. Kopchak,Kofi Oppong,Colin J. McKay,Truls Hauge,Kevin C. Conlon,Mustapha Adham,Güralp O. Ceyhan,Roberto Salvia,Christos Dervenis,Peter J. Allen,François Paye,Detlef K. Bartsch,Matthias Löhr,Massimiliano Mutignani,Johanna Laukkarinen,Richard D. Schulick,Roberto Valente,Thomas Seufferlein,Gabriele Capurso,Ajith K. Siriwardena,John P. Neoptolemos,Aldis Pukitis,Ralf Segersvärd,Ali A. Aghdassi,Stefano Andrianello,Peter Bossuyt,Robin Bülow,Karina Cárdenas-Jaén,P. Cortegoso,Martina Fontana,Lena Haeberle,M. Heckler,Andrey Litvin,Kulbir Mann,Christoph W. Michalski,Patrick Michl,Gennaro Nappo,Giampaolo Perri,S. Persson,F. Scheufele,Francesco Sclafani,Manuel Schmidt,L. Venezia,F. Volker,M-P Vullierm,L. Wusten +88 more
TL;DR: A conservative approach is recommended for asymptomatic MCN and IPMN, and Lifelong follow-up of IPMN is recommended in patients who are fit for surgery.
Journal ArticleDOI
Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
David C. Whitcomb,Glen A. Lehman,Galina Vasileva,Ewa Malecka-Panas,Natalya Gubergrits,Yannan Shen,Suntje Sander-Struckmeier,Steven Caras +7 more
TL;DR: Pancrelipase delayed-release 12,000-lipase unit capsules were effective in treating fat and nitrogen maldigestion with a TEAE rate similar to that of placebo in patients with EPI due to CP or PS.
Journal ArticleDOI
European Guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations:
J-Matthias Löhr,Ulrich Beuers,Miroslav Vujasinovic,Domenico Alvaro,Jens Brøndum Frøkjær,Frank Buttgereit,Gabriele Capurso,Emma L. Culver,Enrique de-Madaria,Emanuel Della-Torre,Sönke Detlefsen,Enrique Dominguez-Munoz,Piotr Czubkowski,Nils Ewald,Luca Frulloni,Natalya Gubergrits,Deniz Güney Duman,Thilo Hackert,Julio Iglesias-Garcia,Nikolaos Kartalis,Andrea Laghi,Frank Lammert,Fredrik Lindgren,Alexey Okhlobystin,Grzegorz Oracz,Andrea Párniczky,Raffaella Pozzi Mucelli,Vinciane Rebours,Jonas Rosendahl,Nicolas Schleinitz,Alexander Schneider,Eric F.H. van Bommel,Caroline S. Verbeke,Marie Pierre Vullierme,Heiko Witt +34 more
TL;DR: Treatment with glucocorticoids should be weight-based and initiated at a dose of 0.6–0.8 mg/kg body weight/day orally for 1 month to induce remission and then be tapered within two additional months.
Journal ArticleDOI
A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
Natalya Gubergrits,E. Malecka-Panas,Glen A. Lehman,G. Vasileva,Y. Shen,S. Sander-Struckmeier,S. Caras,David C. Whitcomb +7 more
TL;DR: Aliment Pharmacol Ther 2011; 33: 1152–1161.
Journal ArticleDOI
Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency.
TL;DR: PERT is effective for treating malnutrition and supporting weight maintenance, and it is associated with improved quality of life and possibly with enhanced survival in patients with PEI, however, there is evidence that not all patients withPEI receive adequate PERT.